Chronoscale Holdings Corp quarterly report, Q1 FY2017

Ekso Bionics Holdings, Inc. — Q1 2017 Form 10-Q

Reporting period: Three months ended March 31, 2017; filed May 9, 2017. The filing describes a company developing and selling exoskeletons for medical, industrial, and engineering-services markets. Unless otherwise noted, financial amounts below are in thousands of dollars.

Financial performance and position

MetricQ1 2017Q1 2016 / comparison
Revenue$1,436$8,486; down 83%
Gross profit and margin$352; 24.5%$1,498; 17.7%
Operating expenses$8,493$8,140; up 4%
Operating loss$(8,141)$(6,642)
Net loss$(8,302)$(3,651); net loss applicable to common shareholders in 2016 was $(6,775), including a $3,124 preferred deemed dividend
Basic and diluted loss per share$(0.38)$(0.44)
Cash used in operations$(7,254)$(6,789)
Cash at period end$9,426$16,846 at December 31, 2016
Total assets / liabilities$16,895 / $18,278Stockholders’ deficit of $1,383 at March 31, 2017

Device and related revenue was $1,408, comprising $870 medical-device and $538 industrial revenue; engineering-services revenue was $28. Cash used in investing was $138, principally for equipment. Financing activities provided $2. The company reported a $69 non-cash loss from revaluing warrant liabilities and $92 of interest and other expense.

At March 31, 2017, note payable was $6,834 net of issuance costs and discount, including $389 current; the loan carries a floating rate of 30-day LIBOR plus 5.41% and matures January 2021. The company reported compliance with its loan covenants, including the requirement to maintain unrestricted cash of at least $6,678. It estimated effective unrestricted cash after that restriction at $2,748. Contractual obligations totaled $10,806, including term-loan, lease, and leasehold-improvement obligations.

Changes versus the prior comparable period

  • Revenue fell 83%. The 2016 comparison included $6,517 of previously deferred medical-device revenue recognized following a change in accounting estimate, contributing $2,358 of gross profit. The filing therefore cautions that the prior-year comparison is affected by this item.
  • Operating loss widened by $1,499, as the revenue decline outweighed a modest increase in operating expenses. Sales and marketing expense rose 23% and R&D rose 34%; G&A fell 27%, largely because 2016 included CEO-related stock-compensation and severance charges.
  • Net loss increased from $3,651 to $8,302. The comparison also reflects a $2,985 warrant-revaluation gain in Q1 2016 versus a $69 loss in Q1 2017, as well as the 2016 preferred deemed dividend when comparing loss applicable to common shareholders.
  • Cash declined by $7,420 during Q1 2017. Cash at March 31 was $7,420 below year-end, while operating cash use was higher than in Q1 2016.

Outlook, risks, and unusual items

  • Going concern and funding: Management stated that cash, including approximately $10.9 million of net proceeds from an April 2017 registered direct offering, would not fund operations for the full year after the financial statements’ issuance date; this raises substantial doubt about the company’s ability to continue as a going concern. Management expected available resources to meet obligations into Q1 2018 and said significant additional financing would be required. Further financing is not assured and could dilute shareholders; absent funding, the company may need to reduce spending or curtail operations.
  • April financing: The company sold 3,732,356 common shares and warrants for 1,866,178 shares, generating approximately $11.7 million gross and $10.9 million net proceeds. Warrants have a $4.10 exercise price, become exercisable six months after issuance, and expire five years after becoming exercisable.
  • Business plans: Management described plans to invest in clinical, sales, and marketing initiatives for rehabilitation, develop a home-use exoskeleton, and advance industrial products. It was pursuing rental channels for EksoZeroG and noted possible growth in medical-device rentals. The filing provides no quantified revenue or earnings guidance.
  • Key execution risks: Financing needs, customer adoption and long sales cycles, competition and technological change, regulatory requirements, clinical-trial outcomes, reimbursement, and intellectual-property protection. The company reported FDA clearance for specified Ekso GT indications, but continued commercial and regulatory risks remain.
  • Other items: The company adopted a stock-compensation accounting change effective January 1, 2017, with a $171 cumulative adjustment to retained earnings. It reported no material adverse effect expected from routine legal matters. Three customers each represented at least 10% of receivables; one customer accounted for 26% of billed revenue in Q1 2017.

Investor verification checklist

  • Confirm how far the April financing extends liquidity, the monthly recalculation of the $6,678 cash covenant, and the status and terms of additional funding plans.
  • Assess whether revenue recovery is supported by recurring device, rental, and service activity rather than the nonrecurring deferred-revenue recognition in Q1 2016.
  • Track sales execution, gross margins, customer concentration, and the cost and results of clinical and product-development programs.
  • Review debt repayment terms, interest-rate exposure, warrant-related liability valuation, and potential dilution from outstanding warrants, options, and subsequent share issuances.
  • Monitor regulatory and clinical developments, reimbursement prospects, and whether management’s stated runway and operational assumptions are achieved.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.